Celldex Therapeutics, Inc. (CLDX)
CLDX moved a median of +0.04% 30 minutes after news, and -0.46% by the close. How CLDX actually reacts to news — the realized, point-in-time move the market made, measured across 256 labeled events over the last three years with zero look-ahead.
CLDX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.12% | 54% | 256 |
| 30-min | +0.04% | 57% | 256 |
| 60-min | +0.43% | 57% | 256 |
| to close | -0.46% | 40% | 253 |
| Middle 50% of CLDX reactions | -0.95% to +1.49% |
|---|---|
| Median reaction (30-min) | +0.04% |
| Measured reactions | 256 |
Half of all Celldex Therapeutics, Inc. news events land between -0.95% and +1.49% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How CLDX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 10 | -1.15% | 30% | -1.07% |
| Coverage initiations | 30 | +0.20% | 53% | +0.39% |
| Rating reiterations | 88 | +0.08% | 53% | +0.37% |
| Price-target raises | 13 | +0.06% | 54% | -0.20% |
| Price-target cuts | 14 | +0.46% | 64% | -1.42% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how CLDX ranks against every other measured name →
That’s how CLDX usually reacts — get an email when it moves on news →Email me when CLDX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CLDX's baseline. Nothing else.
Recent CLDX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints | Press release | GlobeNewswire | +1.56% | -8.44% | |
| Form 8-K Celldex Therapeutics, For: Sep 22 | SEC filing · Form 8-K | SEC EDGAR | +1.56% | -8.44% | |
| Celldex to Present at Upcoming Investor Conference | Press release | GlobeNewswire | +0.94% | -0.44% | |
| Celldex Reports Second Quarter Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +0.85% | -0.38% | |
| Form 10-Q Celldex Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.85% | -0.38% | |
| Form 8-K Celldex Therapeutics, For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +0.85% | -0.38% | |
| Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis | Press release | GlobeNewswire | +6.38% | +2.78% | |
| Celldex Announces Planned Transition of Chief Financial Officer | Press release | GlobeNewswire | -1.04% | -5.58% | |
| Form 8-K Celldex Therapeutics, For: Jul 10 | SEC filing · Form 8-K | SEC EDGAR | -1.04% | -5.58% | |
| Form 8-K Celldex Therapeutics, For: Jun 25 | SEC filing · Form 8-K | SEC EDGAR | +0.53% | +3.52% | |
| Form S-8 Celldex Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +1.10% | +6.00% | |
| Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting | Press release | GlobeNewswire | +1.09% | +2.65% | |
| Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting | Press release | GlobeNewswire | +1.09% | +2.65% | |
| Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress | Press release | GlobeNewswire | +0.29% | +1.87% | |
| Celldex Reports First Quarter Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -3.38% | -2.78% | |
| Form 10-Q Celldex Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -3.38% | -2.78% | |
| Form 8-K Celldex Therapeutics, For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -3.38% | -2.78% | |
| Form ARS Celldex Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.95% | -1.80% | |
| Form DEF 14A Celldex Therapeutics, For: Jun 25 | SEC filing · Form DEF | SEC EDGAR | +0.95% | -1.80% | |
| Celldex to Present at Upcoming Investor Conference | Press release | GlobeNewswire | +0.58% | +2.15% | |
| Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares | Press release | GlobeNewswire | +0.14% | -0.03% | |
| Form 8-K Celldex Therapeutics, For: Apr 01 | SEC filing · Form 8-K | SEC EDGAR | -0.92% | +5.97% | |
| Celldex Announces Pricing of $300 Million Public Offering of Common Stock | Press release | GlobeNewswire | -0.92% | +5.97% | |
| Celldex Announces Proposed Public Offering of Common Stock | Press release | GlobeNewswire | -0.92% | +5.97% | |
| Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026 | Press release | GlobeNewswire | +0.50% | -1.88% | |
| Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease | Press release | GlobeNewswire | +1.59% | +0.20% | |
| Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAA | Press release | GlobeNewswire | -0.09% | +1.97% | |
| Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria | Press release | GlobeNewswire | +10.25% | +20.63% | |
| Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +0.39% | -0.74% | |
| Form 10-K Celldex Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.39% | -0.74% | |
| Form 8-K Celldex Therapeutics, For: Feb 25 | SEC filing · Form 8-K | SEC EDGAR | +0.39% | -0.74% | |
| Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab’s First-in-Class and Best-in-Disease Profile | Press release | GlobeNewswire | +2.28% | +2.83% | |
| Celldex to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | -0.55% | +4.51% | |
| Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism | Press release | GlobeNewswire | -0.64% | -5.45% | |
| Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer | Press release | GlobeNewswire | +0.41% | -2.62% | |
| Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +1.84% | +9.58% | |
| Form 10-Q Celldex Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.84% | +9.58% | |
| Form 8-K Celldex Therapeutics, For: Nov 10 | SEC filing · Form 8-K | SEC EDGAR | +1.84% | +9.58% | |
| Celldex to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | -1.76% | -1.55% | |
| Celldex Presents Additional Positive Data Demonstrating Barzolvolimab’s Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria (CSU) Study | Press release | GlobeNewswire | -1.02% | -0.98% | |
| Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sustained Efficacy and Favorable Safety Profile over 20 Week Placebo Controlled Treatment Period; Up to 66% of Patients wi | Press release | GlobeNewswire | -1.02% | -0.98% | |
| Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition | Press release | GlobeNewswire | +2.75% | +2.81% | |
| Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025 | Press release | GlobeNewswire | -0.16% | -0.33% | |
| Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference | Press release | GlobeNewswire | -0.23% | +3.36% | |
| Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE) | Press release | GlobeNewswire | +2.66% | -4.87% | |
| Form 8-K Celldex Therapeutics, For: Aug 19 | SEC filing · Form 8-K | SEC EDGAR | +2.66% | -4.87% | |
| Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +4.19% | +1.92% | |
| Form 10-Q Celldex Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +4.19% | +1.92% | |
| Form 8-K Celldex Therapeutics, For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | +4.19% | +1.92% | |
| Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025 | Press release | GlobeNewswire | -5.69% | -5.09% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CLDX section they belong to.
Where else CLDX is measured.
CLDX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | 257 | -0.63% | 42% |
| Addus HomeCare Corporation (ADUS) | 256 | -0.02% | 47% |
| Prothena Corporation plc - Ordinary Shares (PRTA) | 256 | -0.04% | 49% |
| Xeris Biopharma Holdings, Inc. (XERS) | 256 | +0.32% | 57% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Celldex Therapeutics, Inc.'s median reaction calculated?
Every labeled CLDX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 256 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 57% of CLDX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CLDX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.